A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-03-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of tafasitamab and lenalidomide
is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.